HLB Life Science Co., Ltd. (KOSDAQ:067630)

South Korea flag South Korea · Delayed Price · Currency is KRW
4,030.00
+155.00 (4.00%)
Jan 2, 2026, 3:30 PM KST
-59.74%
Market Cap491.04B
Revenue (ttm)114.33B
Net Income (ttm)-178.33B
Shares Out121.85M
EPS (ttm)-1,434.56
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume576,851
Average Volume372,217
Open3,970.00
Previous Close3,875.00
Day's Range3,935.00 - 4,075.00
52-Week Range3,105.00 - 11,940.00
Beta-0.13
RSI56.47
Earnings DateMar 19, 2026

About HLB Life Science

HLB Life Science Co., Ltd. develops and manufactures in vitro diagnostic medical devices and quasi-drugs in South Korea and internationally. It also develops Rivoceranib, a small-molecule tyrosine kinase inhibitor for the treatment of various cancers, including gastric cancer, colon cancer, hepatocellular carcinoma, non-small cell lung cancer, breast cancer, mesothelioma, renal cell carcinoma, and neuroendocrine tumors; and Pyrotinib, an anticancer drug that inhibits the proliferation, division, and survival of cancer cells. In addition, the co... [Read more]

Sector Utilities
Founded 1998
Employees 153
Stock Exchange KOSDAQ
Ticker Symbol 067630
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.